Search Press releases

27 Sep 2024

Transparency notification BlackRock, Inc.

Read More
27 Sep 2024

UCB announces late-breaking two-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024

Read More
26 Sep 2024

Transparency notification BlackRock, Inc.

Read More
25 Sep 2024

Transparency notification BlackRock, Inc.

Read More
25 Sep 2024

UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024

Read More
24 Sep 2024

Transparency notification BlackRock, Inc.

Read More

Stay up-to-date on the latest news and information from UCB